CTOR Company Profile and Key Details

CTOR has shown mixed momentum, losing -1.87% over the past week and -38.24% over the past quarter, though year-to-date performance is up 5.0%. Short-term trend indicators are mixed aligned (SMA20 -3.88%, SMA50 -3.19%, SMA200 -32.83%). The stock’s 14-day RSI is 43.99 (neutral), while the ATR of 0.08 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -82.39% below its high and over 97.97% above its low. Average 10-day trading volume of 41.59 thousand shares is below the 3-month average of 79.57 thousand, indicating normal recent market interest.

Citius Oncology, Inc. has 78.37 million shares outstanding. The public float is 16.37 million shares, elevated short interest at 2.46% of float. This equals 303.36 thousand shares. The short ratio is 0.84 days. Institutional investors hold 75.26% of the float. Insiders own 79.64%.

Citius Oncology, Inc. generated EPS of -$0.31 over the past year. Five-year average earnings growth is -309.67%. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 1 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $6.00 to $6.00. The high target offers 782.35% upside. The low target suggests 782.35% downside. The mean target is $6.00. This offers 782.35% upside. Citius Oncology, Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended May 15, 2026, missed forecasts by 2600.0%. The prior quarter beat by 50.0%. Over the last six quarters, Apple has recorded several small beats. These include 22.22% in May 14, 2025.

Dividend and splits history remains an important factor for investors monitoring long-term returns.

Citius Oncology, Inc. (NASDAQ:CTOR) closed at $0.70 USD, gaining $0.02 (3.32%) from the previous close of $0.68. The stock is currently mid-range between its 52-week high and low $0.49 and $5.24. With a market capitalization of about $65.37 million, Citius Oncology, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~3.42). Key stats such as the average daily volume over the past year has been around 88.71 thousand shares, trading with heavier-than-usual volume. Headquartered in New York City, NY, Citius Oncology, Inc. operates in the Healthcare sector and the Drug Manufacturers - General industry. Led by CEO Leonard L. Mazur, the company employs approximately 285 people and listed since December 08, 2022. Citius Oncology, Inc. concentrates on advancing innovative, targeted therapeutic solutions for various cancer types.

Citius Oncology, Inc. trades at a P/E ratio of -1.45, slightly below the S&P 500 average, with a price-to-sales ratio of 11.27 and a price-to-book ratio of 1.93 suggesting the stock is closer to book value. The P/FCF stands at -3.75, also above market averages.

Citius Oncology, Inc. (NASDAQ:CTOR) shares are flat 5.0% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Citius Oncology, Inc. trading at a premium to the broader market with a P/E of -1.45. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $4.50, suggesting 561.38% upside. Our AI forecast model points to short-term weakness (-8.88% over two weeks), a medium-term rise (514.34% over three months), and a longer-term loss (-92.65% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Citius Oncology, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -8.88%, with price expected at $0.62 by July 16, 2026, within a range of $0.57 to $0.66 3-Month Outlook: Projected rise of 514.34%, reaching $4.18 by September 30, 2026, with a range of $3.22 to $4.81. 1-Year Outlook: Projected loss of -92.65%, with price at $0.05 by July 02, 2027, within a range of $0.00 to $0.00.